Figure 3. (A) The ROC curve (a) showed that CLDN10 expression can be used as a biomarker distinguishing PTC from normal thyroid tissues (GSE35570; AUC=0.954 (95%CI=0.899-0.984); Specificity=0.9804, Sensitivity=0.9077). The survival curve (b) showed that PTC patients with high CLDN10 expression levels had a longer overall survival time relative to those with low CLDN10 expression ones (P<0.05). (B) CLDN10 expression in PTC tissues and adjacent normal tissues assayed by IHC (×10). (a) cancer tissue; (b) para-cancer tissue; (c) cancer vs normal, P<0.05. (C) The association of CLDN10 protein expression levels with clinical features based on a tissue chip. (a) LNM, N0 vs N1, P<0.05; (b) Age, <45y vs >=45y, P>0.05; (c) Clinical stage, I+II vs III+IV, P>0.05; (d) T stage, T1+T2 vs T3+T4, P>0.05.